On October 25, 2023, Nykode Therapeutics AS closed the transaction. The company amended the terms of the transaction and announced that it has issued 29,549,400 new common shares at a price of NOK 17.10 per share for the gross proceeds of up to NOK 505.29474 million.
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
14.67 NOK | -0.41% | +7.79% | -31.45% |
May. 14 | Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.45% | 448M | |
+8.57% | 114B | |
+10.55% | 104B | |
-12.71% | 22.41B | |
-0.32% | 22.28B | |
-5.75% | 19.07B | |
-37.36% | 18B | |
-5.68% | 17.89B | |
+6.98% | 14.28B | |
+36.59% | 12.55B |
- Stock Market
- Equities
- VACC Stock
- News Nykode Therapeutics
- Nykode Therapeutics AS announced that it has received NOK 505.29474 million in funding